Literature DB >> 20233326

Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer.

C-J Liu1, S-Y Kao, H-F Tu, M-M Tsai, K-W Chang, S-C Lin.   

Abstract

BACKGROUNDS: Oral squamous cell carcinoma (OSCC) is a worldwide disease. MicroRNAs are endogenously expressed non-coding RNAs that have important biological and pathological functions. miR-31 was found markedly up-regulated in OSCC and several other malignancies. However, miR-31 expression was also down-regulated in the metastasis process of breast carcinoma.
MATERIALS AND METHODS: Using quantitative RT-PCR analysis, we identified plasma miR-31 in OSCC patients (n = 43) and case controlled individuals (n = 21). Nine OSCC patients saliva were also analyzed. The Mann-Whitney test and Wilcoxon matched pairs test were used to compare the differences among the various clinical variants.
RESULTS: miR-31 in plasma was significantly elevated in OSCC patients relative to age and sex-matched control individuals. This marker yielded a receiver operating characteristic curve area of 0.82 and an accuracy of 0.72 defined by leave-one-out cross-validation. In addition, the plasma miR-31 in patients was remarkably reduced after tumor resection suggesting that this marker is tumor associated. Our preliminary analysis also demonstrated the feasibility of detecting the increase of miR-31 in patient's saliva.
CONCLUSION: This study concluded that plasma miR-31 could be validated a marker of OSCC for diagnostic uses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233326     DOI: 10.1111/j.1601-0825.2009.01646.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  108 in total

Review 1.  Cell-free microRNAs as cancer biomarkers: the odyssey of miRNAs through body fluids.

Authors:  Mohammad Amin Javidi; Amir Hossein Ahmadi; Babak Bakhshinejad; Nazila Nouraee; Sadegh Babashah; Majid Sadeghizadeh
Journal:  Med Oncol       Date:  2014-11-02       Impact factor: 3.064

Review 2.  Noninvasive micromarkers.

Authors:  Janani Saikumar; Krithika Ramachandran; Vishal S Vaidya
Journal:  Clin Chem       Date:  2014-01-09       Impact factor: 8.327

3.  Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients.

Authors:  Eman A Toraih; Eman A Mohammed; Sherif Farrag; Nevene Ramsis; Somaya Hosny
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

4.  Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma.

Authors:  Zujian Chen; Yi Jin; Dongsheng Yu; Anxun Wang; Ishrat Mahjabeen; Cheng Wang; Xiqiang Liu; Xiaofeng Zhou
Journal:  Oral Oncol       Date:  2012-03-17       Impact factor: 5.337

Review 5.  Epigenetic mechanisms in oral carcinogenesis.

Authors:  Jacqueline A Gasche; Ajay Goel
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

Review 6.  The mix of two worlds: non-coding RNAs and hormones.

Authors:  Maitri Y Shah; George A Calin
Journal:  Nucleic Acid Ther       Date:  2012-10-10       Impact factor: 5.486

7.  Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer.

Authors:  Anvesha Srivastava; Simeng Suy; Sean P Collins; Deepak Kumar
Journal:  Mol Cell Pharmacol       Date:  2011

Review 8.  MicroRNAs: history, biogenesis, and their evolving role in animal development and disease.

Authors:  M Bhaskaran; M Mohan
Journal:  Vet Pathol       Date:  2013-09-17       Impact factor: 2.221

9.  Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer.

Authors:  Xin Min Xu; Jian Chang Qian; Zhou Lu Deng; Zhe Cai; Tao Tang; Peng Wang; Ke Hua Zhang; Jian-Ping Cai
Journal:  Oncol Lett       Date:  2012-05-14       Impact factor: 2.967

10.  Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer.

Authors:  Juan Wei; Lian-Ke Liu; Wen Gao; Cheng-Jun Zhu; Yi-Qian Liu; Ting Cheng; Yong-Qian Shu
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.